ArticleDiscover oncology2025

Serum CDC42 level change during abiraterone plus prednisone treatment and its association with prognosis in metastatic castration-resistant prostate cancer patients.

Yong Ma et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.